Search results
Showing 691 to 705 of 2026 results for nice guidelines
Find out more about the types of organisations that can register to be a stakeholder at NICE.
Using NICE guidance in social work: scenarios for principal social workers
Home Implementing NICE guidance Social care...
Subscribe to our GP reference panel and contribute to the development of NICE guidance in a quick and easy way.
Our modular updates framework ensures flexibility and consistency in updating our manuals and helps prioritise important updates.
NICE no longer plans to develop guidance on Freelite assays for diagnosing multiple myeloma and related conditions in primary care.
Show all sections
Sections for HTG619
Evidence-based recommendations on electroconvulsive therapy (ECT) for treating catatonia, prolonged or severe manic episodes or schizophrenia in adults.
This indicator covers the percentage of mothers who give their babies breast milk in the first 48 hours after delivery. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG33
This indicator covers the the percentage of patients with a current diagnosis of heart failure with reduced ejection fraction, who are currently treated with an angiotensin-converting enzyme inhibitor or angiotensin receptor-neprilysin inhibitor or angiotensin II receptor blocker, a beta blocker, a mineralocorticoid receptor antagonist and a sodium glucose co-transporter-2 inhibitor. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
Dapagliflozin in combination therapy for treating type 2 diabetes (TA288)
Evidence-based recommendations on dapagliflozin (Forxiga) given with other drugs for treating type 2 diabetes in adults.
We're working with colleagues to ensure that virtual wards are used in a way that maximises the value for patients and the NHS.
Biographies and registered interests for members of the Technology Appraisal Committee A
Biographies and registered interests for members of the Technology Appraisal Committee A
Evidence-based recommendations on ivabradine (Procoralan) for treating chronic heart failure in adults.
Cenobamate for treating focal onset seizures in epilepsy (TA753)
Evidence-based recommendations on cenobamate (Ontozry) for treating focal onset seizures with or without secondary generalised seizures in adults with drug-resistant epilepsy that has not been adequately controlled with at least 2 antiseizure medicines.
This indicator covers patient experiences of GP services. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes